Bellicum Pharmaceuticals, Inc. (BLCM)의 가격은 얼마입니까?

Bellicum Pharmaceuticals, Inc. (BLCM)의 가격은 $0.07475입니다.

Bellicum Pharmaceuticals, Inc. (BLCM)의 시가 총액은 무엇입니까?

Bellicum Pharmaceuticals, Inc. (BLCM)의 시가 총액은 $755.60K입니다.

Bellicum Pharmaceuticals, Inc. (BLCM) PSR

Bellicum Pharmaceuticals, Inc. (BLCM) operates as a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing innovative cellular immunotherapies. Its primary objective is to combat blood cancers and solid tumors across domestic and global markets. Among its pipeline of experimental therapies are two key GoCAR-T candidates currently undergoing Phase 1/2 clinical evaluations. BPX-601, an autologous therapy, targets solid tumors that exhibit the prostate stem cell antigen. Additionally, BPX-603, a dual-switch GoCAR-T treatment, is being investigated for solid tumors characterized by the human epidermal growth factor receptor 2 (HER2) antigens. The company also features Rivo-cel, an allogeneic T cell therapy designed to improve patient prognoses in cases of leukemias, lymphomas, and various inherited blood disorders. Bellicum maintains strategic partnerships and licensing arrangements with several entities, including Adaptimmune Therapeutics plc, Agensys, Inc., BioVec Pharma, Inc., ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Established in 2004, the company's corporate headquarters are located in Houston, Texas.

연도	P/S 비율	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

P/S 비율

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	P/S 비율	P/S 비율 차이	국가
Vertex Pharmaceuticals Incorporated VRTX.US	9.88	-	US
Argenx SE ARGX.US	10.30	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	4.98	-	BE

회사

P/S 비율

P/S 비율 차이

국가